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ABSTRACT
The emergence of mutations in nucleic acids is one of the major factors underlying evolution, providing
the working material for natural selection. Most bacteria are haploid for the vast majority of their genes
and, coupled with typically short generation times, this allows mutations to emerge and accumulate
rapidly, and to effect significant phenotypic changes in what is perceived to be real-time. Not least
among these phenotypic changes are those associated with antibiotic resistance. Mechanisms of
horizontal gene spread among bacterial strains or species are often considered to be the main mediators
of antibiotic resistance. However, mutational resistance has been invaluable in studies of bacterial
genetics, and also has primary clinical importance in certain bacterial species, such as Mycobacterium
tuberculosis and Helicobacter pylori, or when considering resistance to particular antibiotics, especially to
synthetic agents such as fluoroquinolones and oxazolidinones. In addition, mutation is essential for the
continued evolution of acquired resistance genes and has, e.g., given rise to over 100 variants of the TEM
family of b-lactamases. Hypermutator strains of bacteria, which have mutations in genes affecting DNA
repair and replication fidelity, have elevated mutation rates. Mutational resistance emerges de novomore
readily in these hypermutable strains, and they also provide a suitable host background for the
evolution of acquired resistance genes in vitro. In the clinical setting, hypermutator strains of
Pseudomonas aeruginosa have been isolated from the lungs of cystic fibrosis patients, but a more general
role for hypermutators in the emergence of clinically relevant antibiotic resistance in a wider variety of
bacterial pathogens has not yet been proven.
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INTRODUCTION
Darwin recognised that variation is the raw
material for ‘natural selection’, and that the
frequency at which evolutionary change occurs
can fluctuate [1]. It is now clear that the accumu-
lation of genetic mutations underlies much of this
variation. Bacteria typically have short generation
times and are able to evolve in what is perceived
to be real-time. This ability to adapt rapidly to
changing conditions is illustrated well by the
development of antibiotic resistance. Each new
antibacterial agent presents bacteria with a new
challenge (i.e., adverse growth conditions on
exposure), and they have consistently risen to,
and overcome, the challenges set.
It is possible to generate spontaneous mutants
in vitro that confer resistance to virtually any
antibiotic, although frequencies vary dramatically
according to the bacterial species and the agent
tested (with most frequencies typically £ 10)6).
Bacteria carrying resistance mutations may be
‘less fit’ initially than wild-type organisms, but
this is often a temporary phenomenon, and
compensatory mutations can arise that limit the
negative effects of the resistance mutations [2–4].
In some cases, resistant mutants with compensa-
tory mutations may be more fit than susceptible
revertants possessing the same compensatory
mutations [5], which might explain why some
mutational resistance can be maintained stably in
the absence of selective pressure, i.e., antibiotic
use. This review discusses mutational resistance
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using specific examples. As such, it cannot be
comprehensive, but rather, seeks to illustrate the
importance of mutation and the principles by
which mutation contributes to the emergence and
diversification of resistance mechanisms.
MUTATION AS THE PRIMARY
EFFECTOR OF RESISTANCE:
ANTIBIOTIC CLASSES
Mutational resistance to rifampicin, fusidic acid
and streptomycin arises readily and may pose
clinical problems in some settings, limiting the
use of these agents as monotherapy. Mutation is
also a common mechanism of resistance to many
synthetic antibacterial agents, such as the fluoro-
quinolones and oxazolidinones, although resist-
ance to these classes arises less readily.
Increasing dependence on the fluoroquinolone
class began in earnest with the launch of cipro-
floxacin in the mid-1980s, and has continued to
the present day. Despite the undoubted clinical
value of the fluoroquinolones, their development
has been beset by many hurdles, and several
compounds have either been withdrawn in late
development or have been withdrawn or strictly
limited post-licensing [6]. Current incarnations
include levofloxacin and moxifloxacin, but further
development is ongoing, with the chief goal being
to extend and improve activity, especially against
Gram-positive cocci and bacteria resistant to
existing members of the class [7].
Fluoroquinolones are bactericidal and target
two homologous enzymes, namely DNA topo-
isomerases II (also known as DNA gyrase) and IV
[8], which are essential for the supercoiling of
bacterial DNA. Both enzymes are composed of
subunits, encoded by gyrA and gyrB (for DNA
gyrase) or parC and parE (for topoisomerase IV).
Development of resistance to fluoroquinolones is
a stepwise process, resulting from the accumula-
tion of amino-acid substitutions in these subunits,
and with increasing numbers of mutations gen-
erally correlating with increasing MICs [8,9].
Most, but not all, of the mutations map into
defined regions of the subunits, designated the
quinolone resistance-determining regions [10].
In Gram-negative bacteria, DNA gyrase tends
to be the primary target for fluoroquinolones.
Mutations in gyrA are found in isolates with low-
level resistance, whereas higher MICs are associ-
ated with additional mutations, particularly in
parC, but also in gyrB and, less commonly, in parE
[10]. Resistance mediated by these mutations is
enhanced by other mutations affecting the expres-
sion of efflux pumps [11–16]. In Gram-positive
species the primary target is usually parC [17–19],
but this varies among quinolones. For example,
ciprofloxacin targets parC, while sparfloxacin
targets gyrA [20]. This target preference can be
engineered by substitutions at the C-7 position of
the quinolone pharmacophore [21]. Other quino-
lones, including the des-fluoroquinolone garen-
oxacin [7], target both DNA gyrase and
topoisomerase IV equally [22], and may be less
prone to select resistance as this would require
simultaneous mutations affecting both proteins.
Linezolid is the first licensed member of the
oxazolidinone class, and has a novel mechanism
of action which prevents protein synthesis by
inhibiting formation of the 70S ribosomal initi-
ation complex. Prevalent mechanisms of resist-
ance to other antibiotics inhibiting protein
synthesis do not confer cross-resistance to oxazo-
lidinones [23–25]. As the oxazolidinones are
synthetic agents, bacteria had no pre-existing
reservoir of resistance genes, but linezolid-resist-
ant enterococci were isolated during pre-licensing
clinical trials [26], and resistance has emerged
post-licensing, albeit infrequently, in enterococci
[27–30], Staphylococcus aureus [31–33], coagulase-
negative staphylococci [34] and streptococci
[35,36]. This resistance is mediated typically by
mutations in the genes that encode 23S rRNA.
Several different mutations have been reported in
laboratory-generated mutants, but a G2576T
mutation is particularly common among resistant
clinical isolates; mutations in the ribosomal pro-
tein L4 have also been described [36].
Unlike, e.g., resistance to rifampicin, linezolid
resistance emerges extremely rarely in the labor-
atory, and accurate quantification of mutation
frequencies is often not possible. The low muta-
tion frequency occurs, in part, because the target
23S rDNA genes are present in multiple copies in
most relevant bacterial species. A single muta-
tional event in one gene copy is generally insuf-
ficient to confer phenotypic linezolid resistance.
Rather, subsequent intra-chromosomal recombi-
nation (also known as gene conversion [37]) is
needed to distribute the mutation(s) to multiple
rDNA alleles. As a result of this, the number of
rDNA alleles carrying known linezolid resistance
mutations correlates with the linezolid MIC
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[38–41]. Also, linezolid-resistant mutants were
selected at lower frequencies from a recombina-
tion-deficient strain of Enterococcus faecalis [42],
and emerged more slowly in a recombination-
deficient strain of Staph. aureus [43]. In the latter
study, the Staph. aureus mutants carried distinct
mutations in different rDNA gene copies, consis-
tent with independent mutational events (rather
than gene conversion); this route to resistance is
statistically improbable in the clinical setting, and
most natural isolates (arising from one mutation
and subsequent recombination) have gene copies
with a single mutation type.
MUTATION AS THE PRIMARY
MECHANISM OF RESISTANCE:
BACTERIA
Although mutational resistance can be selected
in vitro, it may not represent the most prevalent
resistance mechanism in clinical isolates of a
particular species. For example, chlorampheni-
col-resistant mutants of Staph. aureus have 23S
rDNA mutations and may be cross-resistant to
linezolid [44], but most clinically significant chlor-
amphenicol resistance in this species is mediated
by acetyltransferase enzymes [45]. However, in
certain species, mutation is the main, or sole,
cause of clinical resistance problems. One of the
best examples is Mycobacterium tuberculosis.
Resistance to all therapeutic agents in this species
is mediated by mutations: i.e., rifampicin resist-
ance in rpoB; isoniazid resistance in katC, inhA,
oxyR, ahpC and furA; streptomycin resistance in
rrs and rpsL; pyrazinamide resistance in pncA;
ethambutol resistance in embB; and fluroquino-
lone resistance in gyrA and gyrB [46]. The treat-
ment of tuberculosis requires combination
therapy to tackle a difficult pathogen that causes
prolonged disease [46,47]; monotherapy is not an
option because of the very real risk of resistance
emerging. Combination therapy decreases, but
does not eliminate, this risk, which is influenced
by the frequencies of mutation to resistance for
each individual agent, and by the number of
bacteria at a focus of infection [46].
Multidrug therapy is also recommended for
Helicobacter pylori infections, typically comprising
triple combination regimens, including two of
clarithromycin, metronidazole, amoxycillin or tet-
racycline, plus a proton pump inhibitor [48].
Chromosomal mutations are responsible for
resistance of H. pylori to clarithromycin (in 23S
rRNA) [49–52], amoxycillin (changes in penicillin-
binding protein 1) [53], metronidazole (in rdxA
and other genes) [48], tetracycline (in 16S rRNA
and other undefined genes) [54,55] and, in vitro,
streptomycin (in rpsL) [56].
RESISTANCE PHENOTYPES CAN BE
ALTERED BY MUTATION
Intrinsic antibiotic resistance is defined as resist-
ance that is characteristic of all members of a
given bacterial species or genus. In many cases,
such resistance results from an inability of the
antibiotic to reach its target (e.g., glycopeptides
are too large to penetrate the outer-membrane of
Gram-negative bacteria), a lack of affinity for the
target (e.g., the penicillin-binding proteins of
Gram-positive bacteria have low affinity for the
monobactam aztreonam), the presence of efflux
pumps (e.g., the multi-substrate pumps of Pseu-
domonas aeruginosa [57] and the lsa-encoded pump
of Ent. faecalis, which confers resistance to the
streptogramin combination quinupristin–dalfopr-
istin [58]), or possession of other chromosomal
resistance mechanisms (e.g., Enterococcus gallina-
rum and Enterococcus casseliflavus ⁄ flavescens pos-
sess D-alanine-D-serine ligases, encoded by vanC
genes, which confer low-level vancomycin resist-
ance [59]). Mutation can affect how such resis-
tances are expressed. For example, nonsense
mutations, resulting in the production of a
truncated Lsa pump, have been identified in
occasional quinupristin–dalfopristin-susceptible
isolates of Ent. faecalis [60], while env mutations,
affecting the cell envelope, can render Neisseria
gonorrhoeae and Eschericha coli susceptible to gly-
copeptides [61,62], and mutations that result in
over-expression of the numerous intrinsic efflux
pumps of P. aeruginosa make a significant contri-
bution, complemented by resistance gene acqui-
sition, towards the multiresistance that is shown
regularly by this species [57,63,64].
AmpC enzymes provide a further example of
an intrinsic resistance mechanism that may be
affected markedly by mutation. These chromoso-
mally-encoded cephalosporinases are found in
many members of the Enterobacteriaceae [65,66].
In some species, such as Esch. coli, AmpC is
usually expressed only at low levels and rarely
has clinical significance. However, AmpC en-
zymes have therapeutic significance in many
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Enterobacter spp. and Citrobacter spp., which typ-
ically express the enzymes inducibly, with the
induction process intimately entwined with cell
wall recycling by AmpD, a process that is affected
by b-lactams. Isolates with an inducible AmpC
are not resistant phenotypically to, e.g., cefotax-
ime and ceftazidime because these agents are
poor inducers of b-lactamase synthesis. However,
if these agents are used to treat infections caused
by AmpC-inducible species, there is a significant
risk that mutants derepressed for AmpC produc-
tion will be selected. For Enterobacter spp., phen-
otypic resistance to cefotaxime and ceftazidime
emerges in c. 20% of bacteraemic patients treated
with third-generation cephalosporins [67], and
can lead to therapeutic failure [68]. Cephalosporin
therapy selects for ampD-null mutants, in which
ampC transcription, no longer regulated negat-
ively by AmpD, is constitutive [69–71].
The introduction of new antibacterial agents
into clinical use provides new pressures, sets new
challenges for bacteria, and can result in the
selection of new resistance types. For example,
AmpC enzymes typically have little activity
against fourth-generation cephalosporins, such
as cefepime and cefpirome, but mutant AmpC
enzymes with activity spectra expanded to in-
clude cefepime and cefpirome have been repor-
ted, both in vitro [72,73] and, more recently, in
rare clinical isolates with chromosomal [74–76] or
plasmid-borne AmpC enzymes [77].
VanA and VanB glycopeptide resistance in
enterococci is mediated by complex clusters of
resistance genes. Both types are usually inducible
and are tightly regulated; membrane-bound VanS
and VanSB peptides sense environmental glyco-
peptides and activateVanRandVanRB,which then
initiate transcription of resistance genes [78–80].
The VanS sensor of a VanA strain recognises both
vancomycin and teicoplanin. However, the VanSB
sensor of a VanB strain does not recognise teico-
planin, with the result that teicoplanin fails to
induce resistance and VanB isolates appear sus-
ceptible to teicoplanin in vitro [59]. In the absence of
glycopeptides, theVanS ⁄VanSBpeptides also act as
negative regulators; they have a phosphatase
domain which deactivates VanR ⁄VanRB and swit-
ches off resistance gene expression [81]. Mutation
can affect the VanS and VanSB sensors, resulting in
changes to the type of glycopeptide resistance
phenotype expressed; changes in the N-terminal
sensordomainofVanS (L50V,E54QandQ69H) can
prevent it from recognising teicoplanin, leading to
a ‘VanB’ phenotype in a genotypic vanA strain
[82,83], while a six-residue deletion in the phos-
phatase domain of VanSB results in constitutive
glycopeptide resistance, including to teicoplanin,
i.e., a VanA phenotype in a genotypic vanB strain
[84]. Mutation can also cause VanA and VanB
enterococci to acquiremoderate levels of resistance
(MICs £ 16 mg ⁄L) to the second-generation glyco-
peptide oritavancin [7,85].
Pleiotropic effects, including increases in anti-
biotic resistance, can be mediated by mutations at
global regulatory loci. The transcriptional activa-
tor MarA, encoded by the marRAB operon [86,87],
regulates transcription of over 60 genes in
Esch. coli, with 76% of these being up-regulated
[88]. Homologues of this regulation system are
found in several enteric Gram-negative genera
[88]. Mutations in marR, encoding a negative
regulator, or marO, the operator to which MarR
binds, affect MarA expression. The Mar pheno-
type is associated with induction of MarA, or with
its constitutive expression following mutational
inactivation of marR. This phenotype includes
non-specific, low-level resistance to fluoroquino-
lones, some b-lactams, chloramphenicol, rifampi-
cin and tetracycline, and also to disinfectants and
organic solvents, as the proteins regulated by
MarA include the AcrAB–TolC efflux pump (up-
regulated) and various outer-membrane proteins
(down-regulated) [87]. Other mutations in MarR
can act as super-repressors of MarA expression
[89]. Resistance associated with MarA expression
can complement other resistance mechanisms in
clinical bacterial isolates [87].
Global regulatory loci occur in many other
bacteria. For example, the virulence regulatory
locus agr [90] may have a role in the development
of intermediate-level resistance to glycopeptides
(GISA phenotype; vancomycin MICs 8–16 mg ⁄L)
in Staph. aureus [91–94]. The precise molecular
basis of this resistance has not been defined, but
the phenotypic characteristics include thickened
cell walls and over-production of D-alanyl-D-
alanine-containing peptidoglycan precursors
[93,95–97]. Glycopeptide-intermediate Staph. aure-
us (GISA) isolates tend to have a disrupted agr
function, and an agr-null mutant gained hetero-
resistance to vancomycin and was tolerant of its
bactericidal effects [98]. Mutations that inactivate
tcaA, which encodes a putative trans-membrane
protein, have also been associated with the GISA
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phenotype, but the precise mechanism of resist-
ance has not been defined [99].
THE ROLE OF MUTATION IN THE
EVOLUTION OF RESISTANCE GENES
Many clinically relevant antibiotic resistance
mechanisms are acquired traits. The resistance
genes encoding them, which may be incorporated
into plasmids, transposons or integrons, or may
exist either as gene cassettes or as partial gene
fragments released from dead bacterial cells, are
acquired by new host strains via horizontal
transfer, mediated by conjugation, transformation
or transduction. These processes are the primary
means of dissemination of acquired resistance
genes, but mutation is essential for the evolution
and diversification of these acquired genes.
In addition to resistance to most penicillins,
extended-spectrum b-lactamases (ESBLs) confer
resistance to second and subsequent generations
of cephalosporins, such as cefuroxime, cefotaxime
and ceftazidime, and to monobactams, but not to
cephamycins or carbapenems [100,101]. Most
plasmid-mediated ESBLs fall into one of two
major families, the TEM- or SHV-type enzymes
[102], found primarily in members of the Entero-
bacteriaceae. The prototypes of these enzyme
families are TEM-1 and TEM-2, which differ from
one another by a glutamine (TEM-1) to lysine
(TEM-2) substitution at residue 39, and SHV-1.
Each is primarily a penicillinase, with no signifi-
cant activity against extended-spectrum cephalo-
sporins, and is susceptible to inhibitors such as
clavulanic acid and tazobactam. However, many
variants of these enzymes have additional muta-
tions which render the enzymes capable of
hydrolysing, e.g., cefotaxime and ceftazidime, or
able to resist the action of b-lactamase inhibitors
[103–105].
At the time of writing, there are 150 TEM
variants and almost 90 SHV variants (http://
www.lahey.org/studies). Among the numerous
variants of the TEM family, likely derivatives of
the TEM-1 or TEM-2 progenitors can be distin-
guished by the presence or absence of residue
Lys39. The evolution of progenitor enzymes by
accumulation of multiple mutations has been
mimicked in vitro [106–108]. Structural studies
have helped to define those mutations that are
critical for expanding the substrate profile of the
TEM enzyme, and others that stabilise enzyme
structure [103,107]. Further mutant variants of
TEM (previously called inhibitor-resistant TEM or
IRT enzymes) and SHV variants confer resistance
to b-lactamase inhibitors. These mutations are
distinct from those that confer ESBL activity.
However, continued selection pressure caused by
wide use of b-lactams has resulted in the emer-
gence of complex mutant TEM enzymes [109–111]
that possess combinations of mutations conferring
ESBL activity with other mutations that provide
small degrees of inhibitor resistance.
Another multi-allelic family of plasmid-medi-
ated ESBLs, the CTX-M enzymes, is currently
causing significant public health concern
[112,113]. In contrast with the TEM and SHV
families, all CTX-M enzymes are ESBLs, with no
known progenitor possessing penicillinase activ-
ity only. Many, possibly all, members of this
family bear witness to the ‘escape’ to plasmids of
chromosomal b-lactamases from Kluyvera spp.
[114–116]. More than 50 CTX-M variants have
been defined, clustering in five phylogenetically
distinct subgroups [112,113] (http://www.lahey.
org/studies). Thus, the appearance of CTX-M
enzymes belonging to separate subgroups in
members of the Enterobacteriaceae represents a
series of independent escape events. However,
intra-subgroup diversification of CTX-M enzymes
again owes much to the accumulation of muta-
tions that alter enzyme activity.
CTX-M enzymes are primarily cefotaximases,
with far greater activity against cefotaxime than
against ceftazidime. However, representatives of
several subgroups (including CTX-M-15, -16, -25,
-27, -28, -29 and -32) have an Asp240Gly substi-
tution, associated with increased catalytic activity
against ceftazidime [113,117–120]. A Pro167Ser
mutation similarly enhances the ceftazidimase
activity of CTX-M-19 [121]. A Ser130Gly mutation
decreased the activity of CTX-M-9 against cefo-
taxime, but increased its resistance to b-lactamase
inhibitors significantly [122].
Besides ESBLs, diverse carbapenemases
belonging to b-lactamase molecular classes A, B
and D are beginning to emerge in non-fermenta-
tive bacteria, especially Pseudomonas spp. and
Acinetobacter spp., and also in members of the
Enterobacteriaceae [123–128]. As with CTX-M
ESBLs, molecular comparisons reveal that these
enzymes represent multiple escape events, and
also that mutation has led to the diversification of
alleles within particular subtypes, most dramat-
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ically with the class D OXA enzymes of Acinetob-
acter spp. [129,130], and among the IMP (22
variants) and VIM (12 variants) class B metallo-
enzymes (http://www.lahey.org/studies).
THE ROLE OF THE HYPERMUTABLE
HOST IN MUTATIONAL RESISTANCE
Genetic change, through the incorporation of
mutations in bacterial DNA, can arise via various
mechanisms, including oxidative [131] and alkyla-
tion [132] damage, and via errors introduced
during DNA replication. Replication errors can
result from failure of three separate processes,
namely base selection, proof-reading and DNA
mismatch repair (MMR), which act sequentially to
ensure the fidelity of replication [133,134]. The first
two processes allow DNA replication to proceed
with a fidelity of 10)7 per bp replicated. The final
step, MMR, recognises DNA base mispairs and
initiates a DNA repair cascade, contributing to
genomic fidelity and yielding a final error rate of
10)10 per bp [135–138]. In Esch. coli, the MMR
pathway is composed of four proteins: MutS
(HexA), MutL (HexB), MutH and UvrD [136,139].
The MMR pathway is crucial in avoiding muta-
tions and maintaining replicative fidelity, thus
modulating genomic fidelity within and between
generations. In any bacterial population, themajor-
ity of isolates has low mutation rates, which
suggests that longer-term genetic stability is
favoured among wild-populations [140]. Bacteria
with defects in their MMR and other repair path-
ways have reduced ability to repair DNA damage,
and are more likely to develop and accumulate
mutations. Such bacteria are said to be ‘hypermut-
able’ and to express a ‘mutator’ phenotype. As
MMR also imposes a barrier to recombination
between divergent sequences, MMR-negative
strains are also hyper-recombinogenic. Suchmuta-
tor phenotypes are not selectable directly but, as an
increased mutation rate can facilitate rapid adap-
tation to changing environments, they can be co-
selected by association with favourable mutations,
such as antibiotic resistance [141,142]. Mutator
strains of Esch. coli can become predominant in a
mixed Esch. coli population under relatively stable
growth conditions [143], and occur at frequencies
of 1)7.5% among pathogenic [144] and commensal
isolates [145]. This indicates the importance of
mutator strains in conferring a short-term selective
advantage under stressful or changing growth
conditions in the wild; moreover, the fact that the
majority of isolates are non-mutators suggests that
mutators are not advantaged under ‘normal’ or
more prevalent growth conditions.
Hypermutators and the cystic fibrosis lung
P. aeruginosa and Staph. aureus are isolated from
the sputum of cystic fibrosis (CF) patients at
frequencies of c. 80% and 33–60%, respectively
[146]. The long-term antibiotic prophylaxis for CF
patients offers good conditions for high rates of
mutation; moreover, an often low rate of bacterial
killing maintains exogenous stress, potentially
elevating further the cellular mutation rate
[142,147] through induction of general stress
systems, such as the SOS response [148,149].
Furthermore, as a highly stressful and fluctuating
environment [150], the CF lung can impose
significant physiological stress on the bacterial
cell in the presence of high concentrations of
antibiotics for protracted periods.
Among CF patients colonised with P. aerugi-
nosa, 29–36% harbour multiply-resistant, hyper-
mutable isolates [151,152]. Most natural isolates of
hypermutable P. aeruginosa harbour lesions in
MMR genes or mutY [150,151] at frequencies
similar to those observed in Esch. coli [145]. While
the frequency of resistance to several antibiotics
was about two-fold greater among the mutator
strains [151], a dearth of molecular investigation
of the resistance mechanisms means that the
importance of hypermutability in the emergence
of multiple resistance in these isolates is un-
known.
During a study of macrolide resistance in
Staph. aureus isolates from CF patients, Prunier
et al. [153] found a higher proportion of hyper-
mutator strains among CF isolates than among
non-CF control isolates. Lesions in mutS were
found in five of 11 hypermutable strains and three
non-hypermutable strains [153]. It was argued
that the higher proportion of hypermutable
strains in CF patients could explain the numerous
ribosomal mutations observed and the associated
macrolide resistance.
Hypermutators and mutators in other
environments
Of almost 30 mutator genes identified in Esch. coli,
only a small proportion have been associated with
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mutator phenotypes among natural isolates of
Esch. coli and salmonellae; these include the mutS,
mutL, mutH and mutU (or uvrD) genes [144]. In
natural populations of Esch. coli, mutators may
occur at frequencies between 0.1% and several
per cent [144,154,155]. Indeed, up to 7.5% of
isolates in uropathogenic populations of Esch. coli
and Shigella spp. have mutation rates elevated
‡ 50-fold above average [156]. Among isolates
from cases of bacteraemia, c. 1% were found to be
mutators, with a ten-fold elevation in mutation
frequency [156]. Recently, < 1% of geographically
diverse isolates from blood and urine cultures
were found to be hypermutators, with mutation
frequencies elevated by > 100-fold. Moreover,
among the study isolates, 23% were found to be
weak mutators, with mutation frequencies ele-
vated by < 100-fold compared with normal [157].
A proposal that a more mutable phenotype could
be related to the pathogenicity of the organism
[144] has been disputed and, to date, remains
unproven [145,156]. Denamur et al. [156] found no
correlation between increased resistance, multiple
resistance, ciprofloxacin resistance or an over-
expressed cephalosporinase and a mutator pheno-
type. In contrast, Gustafsson et al. [158] detected
a significant increase in the rate of mutation
to rifampicin resistance among isolates from
patients with high antibiotic usage, suggesting
that antibiotic usage could enrich for bacterial
populations with elevated mutation rates.
In Acinetobacter baumannii, mutations in mutS
increase the rate of mutation to rifampicin resist-
ance by c. 50-fold [159]. Recently, Davies et al.
[160] reported a clinical isolate with an elevated
rate of mutation to ciprofloxacin resistance (via
gyrA mutations). Part of its MutS sequence was
identical to those of ciprofloxacin-resistant clinical
isolates, which suggests that selection of cipro-
floxacin-resistant A. baumannii could also select
for strains with elevated mutation frequencies.
Among the epidemic serogroup A of Neisseria
meningitidis, 11% of the isolates tested were
mutators, correlating with defects in mutS or
mutL [161]. Hypermutable strains have also been
found among clinical isolates of H. pylori, but the
role of mutS seems doubtful, raising the possibil-
ity that other mutator loci could be important for
a hypermutable phenotype in this organism [162].
Studies of Gram-positive pathogens outside of
the CF lung have found mixed evidence for the
existence of mutators. A laboratory study has
shown that in mixed cultures of hypermutable
(hexA) and wild-type Staphylococcus pneumoniae,
exposure to low concentrations of cefotaxime
enriched the hypermutable isogen [163], thus
increasing the risk of further acquisition of anti-
biotic resistance. Among 200 clinical isolates of
Streptococus pneumoniae, 8.5% were found to be
hypermutable on the basis of their frequencies of
mutation to rifampicin resistance. However,
mutations in hexA (mutS) and hexB (mutL) could
not be associated unequivocably with hypermut-
ability, raising the possibility that additional
mutator loci could be involved in the observed
mutator phenotypes [164].
As discussed above, resistance to linezolid is
rare, and is a compound function of mutation and
recombination events. The emergence of linezolid
resistance during therapy has provided pairs of
pre- and post-therapy isolates from the same
patient, allowing examination of the relationship
between the emergence of resistance, the cellular
mutation rate and the genes encoding the MMR
system pre- and post-resistance development. As
many as seven amino-acid substitutions were
found in the MutSL proteins among 13 clinical
isolates of Enterococcus faecium, which included
two pairs of resistant ⁄ susceptible isolates and two
epidemiologically unrelated susceptible isolates
[165]. The relevance of some of these substitutions
was questioned, but the multiresistant nature of
the isolates did not allow determination of muta-
tion frequencies for resistance to other antibiotics
[165].
During testing of a further oxazolidinone,
AZD2563, a low rate of emergence of mutational
resistance was observed in vitro [166], as for
linezolid. The isolation of a resistant mutant of a
clinical isolate of Ent. faecalis was possible at a
frequency of c. 10)8, and the mutant was hetero-
zygous for a G2576T mutation in the 23S rRNA.
This strain was not thought to show a hypermut-
able phenotype [166], but re-evaluation indicated
that it possessed an elevated rate of mutation to
fosfomycin resistance at 4 · MIC (M. J. Ellington,
unpublished observation). To date, no study has
determined the mutation rates among a series of
clinical isolates in which linezolid resistance has
emerged. Studies to examinemutation frequencies
and correlate them with MMR defects and poly-
morphisms should be a priority for the future.
A survey of rates of mutation to rifampicin and
fusidic acid resistance among 493 clinical isolates
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of Staph. aureus from non-CF patients did not
reveal any mutators, suggesting that they are rare
outside of the CF lung [167]. Mutations are almost
certainly responsible for the low levels of vanco-
mycin resistance (MIC 8 mg ⁄L) that are typical of
GISA. The precise molecular mechanism has not
been defined, but thickening of the cell wall is a
consistent phenotypic consequence [95,168–170].
Theoretically, this phenotype could arise more
readily in a hypermutable background, and a
frameshift causing a premature truncation of the
MutS protein was reported in the original GISA
strain, Mu50 [171,172]. Two mutS-disrupted con-
structs of Staph. aureus RN4220 showed elevated
frequencies of mutation to antibiotic resistance,
including resistance to vancomycin [167,172].
However, O’Neill and Chopra [173] found no
evidence for a mutator phenotype in Mu50 or six
other GISA clinical isolates [173], and demonstra-
ted that the mutS gene of strain Mu50 is intact
[167]. Further studies have revealed that GISA
phenotypes tend to develop more readily in
methicillin-resistant Staph. aureus strains than in
related methicillin-susceptible Staph. aureus
strains [174], and that some isolates have amino-
acid changes in MutS [175]. However, the absence
of mutation frequency data for these strains
means that the phenotypic relevance of these
changes is unknown. Overall, there is no convin-
cing evidence supporting a positive role for
mutators in the emergence of GISA strains.
In summary, there is significant evidence for the
presence of mutator strains among natural popu-
lations of some bacterial pathogens. However, the
frequency of mutators varies dramatically from
study to study, and often does not correlate well
with antibiotic-resistant strains known to have
developed mutational resistance. The diversity of
findings perhaps reflects the complexity and vari-
ability of the environments in which pathogenic
bacteria exist. Moreover, it also seems possible that
some mutator phenotypes may easily revert gen-
etically or be inducible. Clearly, hypermutationhas
a potential role in the development of antibiotic
resistance [152,176–178], but work is required to
gain a comprehensive understanding of its impact
in the clinical setting. Potential areas of significance
for further investigations include patients receiv-
ing long-term nitrofurantoin treatment, as this
antibiotic appears to require many mutations for
resistance to emerge, and animals reared using
antibiotics as growth promoters.
CONCLUSIONS
Mutation as a cause of antibiotic resistance has the
greatest clinical impact on particular antibiotic
classes or in particular bacterial pathogens. How-
ever, it can also alter the way in which resistance
genes are expressed and, in the longer term, can
play a significant role in the evolution and
diversification of acquired resistance determi-
nants. If chromosomal mutation remains the main
resistance mechanism for a ‘bug–drug’ combina-
tion, then there should be concern regarding the
potential for spread of the resistant bacterial
strains, rather than of resistance genes. There is
clear potential for mutational resistance to
emerge, including resistance to agents not yet
licensed for clinical use, and this aspect should be
investigated during the development process of
new compounds. Such studies may help to inform
the choice of suitable dosing regimens for agents
awaiting a licence, in order to better prevent the
emergence of resistance.
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